- Podcast Series
- Targeted Therapies in Lung Cancer 2023
- ASCO® 2023
- Lung Cancer OncTalk
- Blood Cancer OncTalk
- 2022 Melanoma Video Library
- OncTalk 2022
- ASCO Lung Review 2022
- ASCO and ESMO Lung Recap
- 2021 Targeted Therapies Patient Forum
- COVID-19
- Lung
- Hematologic Oncology
- Head and Neck
- Brain
- Palliative
- Genitourinary
- General
- Breast
Playback speed
10 seconds
Expert Analysis of 1L EGFR+ Advanced NSCLC Options: 1st Gen Gefitinib & Erlotinib, 2nd Gen Afatinib & Dacomitinib, 3rd Gen Osimertinib, Combos With VEGF or Chemo, Exon 20 Insertions
By
GRACE
FEATURING
Jared Weiss
By
GRACE
FEATURING
Jared Weiss
197 views
March 1, 2021
Login to view comments.
Click here to Login
Lung